Loading…
Chongqing pharma and distribution group known for its Huoxiang Zhengqi traditional digestive-remedy liquid.
Chongqing pharma and distribution group known for its Huoxiang Zhengqi traditional digestive-remedy liquid.
Pharmaceutical distribution adds large sales volume at thin margins, while the branded remedy and other over-the-counter products sold through pharmacies carry most of the profit. The distribution arm supplies drugs and medical products to hospitals and pharmacies in the Chongqing region.
In one line: A Chinese TCM OTC and distribution conglomerate.
Moat: narrow (brand, distribution). Long-established OTC brand plus a regional pharma distribution network.
Headquarters: Chongqing, China · Employees: 10,864
Size Chongqing Taiji Industry (Group) (600129.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.09B, the 2136th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.23 on 6 Nov 2026.
Performance Over six months the shares fell 15.0%, against -17.7% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 4.5% over the last twelve months (peer median +8.7%); the operating margin is 1.5% (peer median 12.8%).
Valuation It trades at 26.5× forward earnings against a peer median of 22.7× (6th most expensive of 14).
Capital Return on invested capital runs 1.1 points below its cost of capital (5.2% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.59B | CN¥10.4B | CN¥12.3B | CN¥15.4B | CN¥14.0B |
| Revenue growth | — | -15% | -20% | +10% | — |
| Gross profit | CN¥3.03B | CN¥2.76B | CN¥4.64B | CN¥7.14B | CN¥6.00B |
| EBITDA | n/a | CN¥812M | CN¥889M | CN¥1.62B | CN¥1.15B |
| Net income | -CN¥19.6M | CN¥121M | CN¥26.7M | CN¥822M | CN¥354M |
| Free cash flow | -CN¥215M | CN¥64.1M | -CN¥1.46B | -CN¥160M | CN¥1.26B |
| Capital expenditure | CN¥400M | CN¥523M | CN¥832M | CN¥836M | CN¥532M |
| Total debt | CN¥6.07B | CN¥6.44B | CN¥5.62B | CN¥4.86B | CN¥5.02B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Chongqing Taiji Industry (Group) 600129.SS | $1.09B | -15% | -4% | 2% | 26.5× | n/a |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600129.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | -6.8% | 6th highest of 21 |
| 6-month return | -15.0% | -17.7% | 9th highest of 21 |
| Distance from 52-week high | -39.8% | -39.7% | 11th highest of 21 |
| Revenue growth (TTM) | -4.5% | +8.7% | 6th lowest of 20 |
| Operating margin | 1.5% | 12.8% | 5th lowest of 20 |
| Forward P/E | 26.5× | 22.7× | 6th most expensive of 14 |
| ROIC minus cost of capital | -1.1 pp | +0.5 pp | 6th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |